Isotretinoin

"Isotretinoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.

Descriptor ID	D015474
MeSH Number(s)	D02.455.326.271.665.202.495.325 D02.455.426.392.368.367.379.249.700.325 D02.455.849.131.495.325 D23.767.261.700.325
Concept/Terms	Isotretinoin Isotretinoin 13-cis-Retinoic Acid 13 cis Retinoic Acid Isotretinoin Zinc Salt, 13-cis-Isomer Isotretinoin Zinc Salt, 13-cis-Isomer Isotretinoin Zinc Salt, 13 cis Isomer Roaccutane Roaccutane Accutane Accutane Ro 4-3780 Ro 4-3780 Ro 4 3780 Ro 43780

Below are MeSH descriptors whose meaning is more general than "Isotretinoin".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Acyclic [D02.455.326]
Alkenes [D02.455.326.271]
Polyenes [D02.455.326.271.665]
Carotenoids [D02.455.326.271.665.202]
Retinoids [D02.455.326.271.665.202.495]
Isotretinoin [D02.455.326.271.665.202.495.325]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Alicyclic [D02.455.426.392]
Cycloparaffins [D02.455.426.392.368]
Cyclohexanes [D02.455.426.392.368.367]
Cyclohexenes [D02.455.426.392.368.367.379]
Carotenoids [D02.455.426.392.368.367.379.249]
Retinoids [D02.455.426.392.368.367.379.249.700]
Isotretinoin [D02.455.426.392.368.367.379.249.700.325]
Terpenes [D02.455.849]
Carotenoids [D02.455.849.131]
Retinoids [D02.455.849.131.495]
Isotretinoin [D02.455.849.131.495.325]
Biological Factors [D23]
Pigments, Biological [D23.767]
Carotenoids [D23.767.261]
Retinoids [D23.767.261.700]
Isotretinoin [D23.767.261.700.325]

Below are MeSH descriptors whose meaning is related to "Isotretinoin".

Below are MeSH descriptors whose meaning is more specific than "Isotretinoin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Isotretinoin" by people in this website by year, and whether "Isotretinoin" was a major or minor topic of these publications.

Bar chart showing 20 publications over 14 distinct years, with a maximum of 3 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	1	0	1
2004	2	1	3
2006	1	0	1
2009	0	1	1
2013	1	0	1
2014	2	0	2
2015	0	1	1
2016	2	0	2
2017	1	0	1
2018	1	0	1
2019	1	0	1
2020	1	1	2
2022	0	2	2

Below are the most recent publications written about "Isotretinoin" by people in Profiles.

Xia E, Han J, Faletsky A, Baldwin H, Beleznay K, Bettoli V, Dr?no B, Goh CL, Stein Gold L, Gollnick H, Herane MI, Kang S, Kircik L, Mann J, Nast A, Oon HH, See JA, Tollefson M, Webster G, Zip C, Tan J, Tapper EB, Thiboutot D, Zaenglein A, Barbieri J, Mostaghimi A. Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study. JAMA Dermatol. 2022 08 01; 158(8):942-948.

View in: PubMed
Paller AS, Browning J, Parish LC, Bunick CG, Rome Z, Bhatia N. Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study. J Am Acad Dermatol. 2022 11; 87(5):1189-1191.

View in: PubMed
Halakos EG, Connell AJ, Glazewski L, Wei S, Mason RW. Bottom up proteomics identifies neuronal differentiation pathway networks activated by cathepsin inhibition treatment in neuroblastoma cells that are enhanced by concurrent 13-cis retinoic acid treatment. J Proteomics. 2021 02 10; 232:104068.

View in: PubMed
Aslan Kayiran M, Karadag AS, Al-Khuzaei S, Chen W, Parish LC. Antibiotic Resistance in Acne: Mechanisms, Complications and Management. Am J Clin Dermatol. 2020 Dec; 21(6):813-819.

View in: PubMed
Halakos EG, Connell AJ, Glazewski L, Wei S, Mason RW. Bottom up proteomics reveals novel differentiation proteins in neuroblastoma cells treated with 13-cis retinoic acid. J Proteomics. 2019 10 30; 209:103491.

View in: PubMed
London NJS, Kaiser RS, Khan MA, Alshareef RA, Khuthaila M, Shahlaee A, Obeid A, London VA, DeCroos FC, Gupta OP, Hsu J, Vander JF, Spirn MJ, Regillo CD. Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial. Br J Ophthalmol. 2019 09; 103(9):1306-1313.

View in: PubMed
Webster GF, Webster TG, Grimes LR. Laboratory tests in patients treated with isotretinoin: occurrence of liver and muscle abnormalities and failure of AST and ALT to predict liver abnormality. Dermatol Online J. 2017 May 15; 23(5).

View in: PubMed
Karadag AS, Parish LC, Lambert WC. Isotretinoin in retrospect. Clin Dermatol. 2017 May - Jun; 35(3):335-339.

View in: PubMed
Tintle SJ, Harper JC, Webster GF, Kim GK, Thiboutot DM. Safe Use of Therapeutic-Dose Oral Isotretinoin in Patients With a History of Pseudotumor Cerebri. JAMA Dermatol. 2016 05 01; 152(5):582-4.

View in: PubMed
Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update. Retina. 2015 Feb; 35(2):165-75.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement